Seer, Inc. (SEER): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how deep, unbiased proteomic analysis could revolutionize scientific outcomes? Seer, Inc. (SEER), a pioneering life science company, is making waves with its Proteograph Product Suite, designed to unlock biological information at scale. But how did Seer get here, who owns it, what's their mission, and how exactly does their technology work and generate revenue? Keep reading to discover the ins and outs of this innovative company, which achieved revenue of $14.2 million for the full year 2024 and shipped a cumulative total of 72 instruments as of December 31, 2024.

Seer, Inc. (SEER) History

Seer, Inc.'s Founding Timeline

Year established

Seer, Inc. was established in 2017.

Original location

The company was originally located in Redwood City, California.

Founding team members

The founding team members included:

• Omead Ostadan
• Robert Neely
• Philip Ma

Initial capital/funding

In 2018, Seer, Inc. secured $35.7 million in Series A funding. This was followed by a Series B round in 2020, which raised $55 million.

Seer, Inc.'s Evolution Milestones

Seer, Inc.'s Transformative Moments

Seer, Inc. has experienced several transformative moments that have shaped its trajectory:

• Technological Breakthroughs: The development and launch of the Proteograph™ Product Suite represented a major technological leap, enabling researchers to explore the proteome with unprecedented depth and scale.
• Strategic Partnerships: Collaborations with other companies, such as the one with Quantum-Si in 2023, have expanded Seer's capabilities and market reach.
• Financial Milestones: Securing substantial funding through Series A and B rounds, as well as the IPO in 2021, provided the capital necessary to fuel growth and innovation.
• Market Adoption: Increasing adoption of the Proteograph™ platform by leading research institutions and pharmaceutical companies has validated Seer's technology and positioned it as a key player in the proteomics field.

For more insights into the company's financial standing, check out: Breaking Down Seer, Inc. (SEER) Financial Health: Key Insights for Investors

Seer, Inc. (SEER) Ownership Structure

Seer, Inc. features a mixed ownership structure comprising institutional investors, individual shareholders, and company insiders. The distribution of shares among these groups influences the company's governance and strategic direction.

Seer, Inc.'s Current Status

Seer, Inc. is a publicly traded company, listed on the Nasdaq Global Market under the ticker symbol SEER. This status allows the company to raise capital through the issuance of stock and makes it subject to regulatory oversight and reporting requirements.

Seer, Inc.'s Ownership Breakdown

The ownership of Seer, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. As of the latest available data, the ownership breakdown is as follows:

Seer, Inc.'s Leadership

Seer, Inc.'s direction is guided by a team of experienced leaders. Key members of the leadership team include:

• Omead Ostadan: President and CEO
• David R. Horn: Chief Financial Officer
• Renee Gallegos: Chief Commercial Officer

For more in-depth information on Seer, Inc. and its investors, check out this resource: Exploring Seer, Inc. (SEER) Investor Profile: Who’s Buying and Why?

Seer, Inc. (SEER) Mission and Values

Seer, Inc. focuses on revolutionizing proteomic analysis to enable early disease detection and precision medicine. The company values innovation, collaboration, and making a significant impact on healthcare.

Seer, Inc.'s Core Purpose

Official mission statement

Seer's official mission statement is: To be the leader in proteomics and revolutionize healthcare through enabling proteomic analysis for early disease detection and precision medicine.

Vision statement

Seer's vision is focused on transforming healthcare through proteomics. This involves:

• Advancing the understanding of the proteome to improve patient outcomes.
• Creating technologies that enable deeper and more comprehensive proteomic analysis.
• Empowering researchers and clinicians with the tools they need for early disease detection and personalized treatment strategies.

Company slogan/tagline

While specific slogans or taglines may vary, Seer, Inc.'s communications often emphasize:

• Innovation in proteomics
• Transforming healthcare
• Enabling precision medicine

For more detailed insights, you can explore: Mission Statement, Vision, & Core Values of Seer, Inc. (SEER).

Seer, Inc. (SEER) How It Works

Seer, Inc. operates by focusing on proteomics, specifically through its Proteograph Product Suite, which enables researchers to deeply analyze proteins in biological samples. This technology aims to provide a more comprehensive understanding of diseases and improve drug development.

Seer, Inc.'s Product/Service Portfolio

Seer, Inc.'s Operational Framework

Seer's operational framework revolves around:

• Technology Development: Continual innovation in proteomics to enhance the capabilities of the Proteograph platform.
• Manufacturing and Quality Control: Production of high-quality Proteograph reagents and consumables to ensure reliable and reproducible results.
• Sales and Marketing: Direct sales and marketing efforts targeting key accounts in biopharma and academia, coupled with participation in scientific conferences and publications.
• Customer Support and Training: Providing comprehensive support and training to users to maximize the utility of the Proteograph system in their research.
• Strategic Partnerships: Collaborating with leading research institutions and biopharmaceutical companies to expand the applications of its technology and drive adoption.

Seer, Inc.'s Strategic Advantages

Seer, Inc. maintains several strategic advantages:

• Proprietary Technology: The Proteograph platform offers unique capabilities in proteomic analysis, providing a competitive edge over traditional methods.
• Comprehensive Proteomic Profiling: Enables deeper insights into the proteome, facilitating biomarker discovery and drug development.
• Scalability: Designed for high-throughput analysis, accommodating large-scale studies and clinical applications.
• Strong IP Portfolio: Robust patent protection safeguarding its technology and market position.
• Expert Team: A team of experienced scientists and engineers dedicated to advancing proteomics and supporting customer needs.

Read more about the company's values: Mission Statement, Vision, & Core Values of Seer, Inc. (SEER).

Seer, Inc. (SEER) How It Makes Money

Seer, Inc. generates revenue primarily through the sale of its Proteograph Product Suite, which includes consumables, instruments, and services related to proteomics research.

Seer, Inc.'s Revenue Breakdown

Here's a breakdown of Seer, Inc.'s revenue streams:

Seer, Inc.'s Business Economics

Seer, Inc.'s business economics are influenced by several key factors:

• Pricing Strategy: Seer employs a premium pricing strategy, reflecting the advanced technology and precision of its Proteograph Product Suite.
• Cost of Goods Sold (COGS): A significant portion of Seer's expenses is related to manufacturing and material costs.
• Research and Development (R&D): Seer invests heavily in R&D to innovate and expand its product offerings. For the year 2024, R&D expenses were $77.5 million.
• Operating Expenses: These include sales, marketing, and administrative costs, which are substantial as Seer expands its market presence. In 2024, these expenses totaled $63.8 million.

Seer, Inc.'s Financial Performance

Key aspects of Seer, Inc.'s financial performance include:

• Revenue Growth: Seer has demonstrated substantial revenue growth, with total revenue for the year 2024 reaching $22.4 million, a 35% increase compared to 2023.
• Gross Margin: Seer's gross margin has improved, reaching 34% for the year 2024.
• Operating Loss: Despite revenue growth, Seer continues to experience an operating loss due to significant investments in R&D and commercial expansion. The operating loss for 2024 was $123.5 million.
• Cash Position: Seer maintains a strong cash position, with $370.5 million in cash, cash equivalents, and investments as of December 31, 2024.

To gain more insights into the investors and stakeholders behind Seer, Inc., explore this resource: Exploring Seer, Inc. (SEER) Investor Profile: Who’s Buying and Why?

Seer, Inc. (SEER) Market Position & Future Outlook

Seer, Inc. is strategically positioned to capitalize on the growing proteomics market with its innovative Proteograph platform, which offers unprecedented depth and speed in proteomic analysis. While the company faces competition and market adoption challenges, its technology holds significant potential for transforming drug discovery and personalized medicine.

Competitive Landscape

Opportunities & Challenges

Industry Position

Seer, Inc. is making strides in the proteomics field. Here's a snapshot of their industry position:

• Focus on Innovation: The company's Proteograph platform is designed to provide comprehensive proteomic data, setting it apart from traditional methods.
• Strategic Collaborations: Forming partnerships to expand technology reach and drive adoption in key research areas.
• Emerging Market: While the proteomics market is still developing, Seer, Inc. aims to establish itself as a key player through technological advancements and strategic initiatives.

To gain deeper insights into the investors and motivations behind Seer, Inc., explore this resource: Exploring Seer, Inc. (SEER) Investor Profile: Who’s Buying and Why?